Cogent Biosciences, Inc.
COGT
Clasificación en acciones
#3264
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Precio por acción
$31.47
Capitalización bursátil
$5.46B
Cambio (1 día)
4.85%
Cambio (1 año)
93.99%
País
US
Comercio Cogent Biosciences, Inc. (COGT)
Categoría
Healthcare
Ratio P/S de Cogent Biosciences, Inc. (COGT)
Ratio P/S al October 2026 TTM: 0.00
Según los informes financieros más recientes y el precio de las acciones de Cogent Biosciences, Inc., el ratio P/S actual (TTM) es 0.00. Al final de 2023, el ratio P/S era 0.00.
Historial del ratio P/S de Cogent Biosciences, Inc. desde 2015 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | 15.81 | 1,520.90% |
| 2019 | 0.98 | -91.33% |
| 2018 | 11.25 | -71.38% |
| 2017 | 39.32 | -3.98% |
| 2016 | 40.95 | -53.01% |
| 2015 | 87.14 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
